HBM Healthcare Investments Ltd

Unique Access to a Global and Diversified Healthcare Portfolio of Private and Public Companies

November 2019

HBM Healthcare Investments Ltd

About HBM Healthcare Investments Ltd

- Investment Strategy / Investment Process
- Healthcare Sector
- **Portfolio Structure**
- **Investment Positions**
- **Outlook & Concluding Remarks**
- Appendix: Organisation, Team

A Leading Investment Company in Healthcare

- Founded in 2001 and listed on SIX Swiss Exchange since 2008
- A healthcare sector focused investment company holding a global diversified portfolio with currently about CHF 1.4bn in net assets
- Portfolio of both promising private and small-cap public companies (generally companies with a market capitalization below USD 2 bn)
- Dedicated Healthcare sector specialist with healthcarerelevant expertise and background as well as access to a broad-based, worldwide network in science, industry and finance
- International, stable ownership structure with significant proportion owned by the HBM team and members of the Board of Directors

The only listed healthcare focused company holding private and public equity

Mid to high teens percentage increase in net asset value and share price over the last five years (p.a.)

Attractive distribution policy (3-5% p.a.)

Facts & Figures


Registered Shares (CHF)

Total assets	1'570 million
Net assets (NAV)	1'416 million
Market capitalisation	1'386 million
Share price	199.20
NAV per share	203.50
Discount	2.1%
Average daily liquidity (1 year)	6'405 shares
	~ 1.3 million
Number of issued shares	6.96 million
Number of shareholders	2'230


Performance (CHF)

Net return (including distributions)	2019	2018	2017	2016	5Y Return p.a.	10Y Return p.a.
Share price	33.0%	21.8%	40.5%	2.5%	20.3%	18.1%
NAV	23.3%	9.9%	25.8%	-7.2%	13.0%	13.8%
Dividend CHF	7.50	7.00	5.80	5.50		
Dividend yield	4.4%	4.9%	5.2%	5.5%		
Share price	5Y Volatility p.a. 16.8%		1Y	⁷ Volatilit 1	y p.a. 7.5%	

Value Creation over 5 Years



Data as of 31 October 2019, indexed (12.7.2001 = 100)




Data as of 31 October 2019


HBM Healthcare Investments Ltd

About HBM Healthcare Investments Ltd Investment Strategy / Investment Process Healthcare Sector Portfolio Structure Investment Positions Outlook & Concluding Remarks Appendix: Organisation, Team

Investment Focus in the Healthcare Sector



HBM Investment Focus along the Healthcare Value Chain




9

HBM Healthcare

Investment Strategy

- ► Focus on companies with promising product pipelines and high value creation potential
- Portfolio of both private and small-cap public companies (generally companies with a market capitalization below USD 2 bn)
- Investments typically first made in a venture round when target company has product(s) is in clinical development and has achieved "proof of concept"
- Subsequently, investment may be increased substantially in follow-on financings, provided the value-creation potential is intact
- Active participation with companies to develop towards trade sale or IPO
- At or post IPO: the flexibility of HBM Healthcare Investments allows for further increasing its investments in the most attractive investment cases

Private Equity Investment Process



Investment Approach

- Fundamental long with private and public healthcare investments
- Bottom-up selection of investments with solid long-term growth potential
- Diversified portfolio approach
- Sourcing of proprietary private deal flow
- Active lead/co-lead investor in private companies with board representation
- HBM takes an active role and assumes entrepreneurial responsibility together with the management team
- Maximum single position limit at time of investment up to 10% of NAV

HBM Healthcare Investments

Public Equity Investment Process

Portfolio & Risk Management

- Evaluation of global markets and macro themes
- Continuous Portfolio review and adjustment
- Comprehensive risk management process

Stock Selection & Portfolio Construction

- Determination of exposure and position size
- Individual stock selection
- Initiating new positions

Idea Generation

- Universe of 750+ companies
- Tracking of healthcare trends incl conference attendances and close relationship to experts and executives
- Company pre-selection

Due Diligence

- Fundamental qualitative and quantitative analysis
- Stakeholder assessment and intellectual property review
- Investment write-up and conclusion

Investment Case Advanced Accelerator Applications

Investment rationale

 Combination of unique business proposition with strong growing medical imaging business (profitable) and promising late-stage therapeutic (phase III)

Investment process (2014)

- Growth capital and partial buyout of existing founders
- Founders wanted specialist (non-US) investor with know-how and good industry network

Investment period (2014-2017)

- Board representation
- Strategy executed on three pillars:
 - Expanding its diagnostic business for PET/CT and SPECT organically and through acquisitions
 - ► Bringing first therapeutic to the market
 - ► Broadening of pipeline through in-house development and in-licensing
- ► HBM backed pre-IPO financing round to strengthen investor syndicate

Exit (2016-2017)

► IPO and take over by Novartis

First institutional investor in 2014

Sold in 2017 to Novartis for approx USD 3.9 billion

→ Gain of over CHF 200 million (IRR > 60%)



Investment Case Skyepharma

Investment rationale

 Uniquely positioned and patented drug delivery technology for oral and inhalation products; significant recurring revenue streams through technology outlicensing

Investment period (2005-2016)

- Pacira was spun-out from Skyepharma
- The delayed approval of Flutiform[®] resulted in indebtedness and negative balance sheet
- HBM led the turnaround financing round and participated in capital increase and debt purchase at high discount
- Positive pipeline development of Flutiform® led to continuous company revaluation, Skyepharma turned into a highly profitable cash flow positive company
- Debt to equity swap allowed share price moving back to fair value


Exit process (2015-2016)

- Further growth source was needed as revenue growth started to flatten out and pipeline investments was very limited during the last years due to restructuring and indebtedness that company went through
- Combination with Vectura resulted in highly attractive new platform of complementary products and technologies



Merger with Vectura in 2016 created a global leader of formulation and inhalation devices for respiratory diseases

Impressive rebound between 2011 and 2016



HBM Healthcare Investments


Investment Case Ellipse Technologies

Business	Medical devices for spinal/orthopaedic surgery Platform technology for non-invasive adjustable implants
Stage of Company	Substantial revenues (sales growth 60%+ p.a.) Products successfully launched worldwide; R&D focus on additional indications
Return on Investment	Multiple of 7.5 – 8.1x IRR 66 – 68 % Gain USD 104 – 114m

Products

- ► MAGEC To treat spine deformations
- ► PRECICE Limb lengthening system

Revenues



 \rightarrow Sold in Jan. 2016 to NuVasive for \$ 380m in cash plus \$ 30m milestones

HBM Healthcare Investments Ltd

About HBM Healthcare Investments Ltd Investment Strategy / Investment Process Healthcare Sector

Portfolio Structure

Investment Positions

Outlook & Concluding Remarks

Appendix: Organisation, Team

Investment Opportunities in Healthcare

Large and Growing Industry

- Revenues > \$1.3 trillion p.a.*
- Resilient to economic cycles
- High profit margins, strong cash-flows
- Many small & innovative firms and spin-offs

HBM Healthcare Investments

Investment Approach


- Proprietary global deal sourcing
- Long-term investment expertise
- Active lead/co-lead investor
- Exit-driven investments

Compelling Exit Markets

- Attractive M&A environment
- Cash-rich corporate buyers
- Strategic premiums paid
- IPO as option for mature firms


* Worldwide sales (2015) for pharma, medtech and diagnostics only

Public Healthcare Generated Strong Returns




Still Significant Industry Growth

Global Pharma Drug Sales




Global Biotech Drug Sales



Source: Evaluate Pharma World Preview 2017, June 2017


Significant Revenue Contribution from Biotech

Global Branded Pharmaceutical Revenues: 1997 – 2020 (in \$ bn)




Source: Evercore Gene Therapy Outlook 2019

Biotech as the Innovation Powerhouse




Source: EY Biotechnology Report 2017, Evaluate Pharma World Preview 2018




Source: MSCI World Healthcare Index, Bloomberg 2018

Pipeline (number of clinical programs, 2017)



Source: Biotechnology Innovation Organization Report, 2018

Approvals by origin (count, over last 10yrs)




Source: HBM Biopharma Drug Approval Report, 2018

It's all about Innovation

	In last 1-2 years, multiple "targeted cancer"	Past and current holdings			
Immuno- and targeted oncology	companies (drugs for mutations or sub-groups of broader population) have been acquired	IMMUNOMEDICS, INC.	TP Therapeutics		
Gene Silencing	 Administered via the bloodstream, in principle RNAi therapeutics permit any gene that is responsible for causing illness to be silenced 	Alnylam			
Gene editing / therapy	 Gene editing is the process of changing, replacing, or removing genes with precision of a single base pair change if desired 	uniQure	AVOESIS L'OMOLOGY Medicines, Inc. CRISPR		
Immunology and Inflammation	 Antibodies have had a terrific run, but small molecules are making a comeback for I&I, promising oral dosing, ease of travel, transport and safety of dose withdrawal 	argenx¥			
Neurology	 Dementia psychosis, agitation, behavioral market have blockbuster potential 	HARMONY	NEURELIS Zogeni &		
	The complement system helps prevent infection and				
Complement disorders	fight off invading pathogens like bacteria. But hyperactivation of the complement system can lead to autoimmunity and inflammatory diseases	Apellis	TRUE NORTH THERAPPUTICS Ra Pharma		


Supportive Regulatory Climate


Number of New Drug Approvals and Applications at the US FDA



Source: FDA, CDER (2017)

Steady Flow of New Investment Opportunities






Biotech IPOs on western exchanges

Ongoing Pharma and Biotech M&A Activity

50% premium over stock price before acquisition



Source: Evaluate Pharma (2019)

HBM Healthcare Investments Ltd

About HBM Healthcare Investments Ltd Investment Strategy / Investment Process Healthcare Sector


Portfolio Structure

Investment Positions Outlook & Concluding Remarks Appendix: Organisation, Team

HBM Healthcare Investments

28


Balance Sheet and Currency Allocation




HBM Research, data as of 31 October 2019, in % of net assets

in % of assets

Portfolio Breakdown by Market Cap and Geography




Portfolio Breakdown by Sector, Therapy and Stage



HBM Healthcare Investments


Investment Portfolio



HBM Research, data as of 31 October 2019, in % of assets, Top 10 positions (direct investments): 37.8%


HBM Healthcare Investments

Asset Allocation over Time



HBM Research, data as of the end of each financial year (31 March), in % of assets


Development Stage of Lead Product of Portfolio Companies



HBM Research, data as of the end of each financial year (31 March), in % of investments

HBM Portfolio by Development Stage of Lead Asset






HBM Research, data as of 30 September 2019

HBM Healthcare Investments

Private Portfolio Positioning




³⁵

HBM Research, data as of 30 September 2019

Contribution to NAV

Private and Ex Private Equity Positions Account for 65 Percent of Contribution

NAV impact per share (in CHF)



Note: IPO allocations in previously private companies are attributed to P&L from private positions

About HBM Healthcare Investments Ltd Investment Strategy / Investment Process Healthcare Sector Portfolio Structure Investment Positions Outlook & Concluding Remarks Appendix: Organisation, Team

38

Global Portfolio



HBM Research, data as of 31 October 2019 (Selection)

Largest Investments (1/2)


Company	Core Business	Phase of Lead Product	Ticker	Market Capitalisation (CHF m)	Owner- ship (%)	Book Value (CHF m)	% of Total Assets
CATHAY INDUSTRIAL BIOTECH	Long chain diacids, carbohydrates and special enzymes	Market	Private	2'628*	7.9	207.5	13.2
-mAbs	Developing novel antibody therapeutics for oncology targets	Phase III	YMAB (ex private)	1'197	7.5	89.6	5.7
HARMONY	Drug for the treatment of narcolepsy (with and without cataplexy)	Phase III	Private	808*	8.0	64.3	4.1
NEURELIS	Late-stage drug for the treatment of acute breakthrough seizures in epilepsy patients	Phase III	Private	253	15.1	38.2	2.4
PHARMACEUTICALS, INC.	Injectable medicines with (patented) controlled release of active drug	Market	PCRX (ex private)	1'665	2.3	38.0	2.4
	Late-stage drug for treatment of severe inflammation and autoimmune diseases	Phase III	VIE (ex private)	1'067	3.5	37.5	2.4

HBM Research, data as of 31 October 2019, * Implied company valuation

Largest Investments (2/2)

Company	Core Business	Phase of Lead Product	Ticker	Market Capitalisation (CHF m)	Owner- ship (%)	Book Value (CHF m)	% of Total Assets
argenx	Drugs for autoimmune and cancer diseases	Phase II	ARGX	4'530	0.8	36.1	2.3
Turning Point	Drugs for the treatment of severe cancers	Phase II	TPTX (ex private)	1'357	2.4	32.3	2.1
Zogenix	Therapeutic solutions for CNS disorders and rare diseases	Phase III	ZGNX	1'943	1.4	27.0	1.7
SpringWorks	Targeted oncology treatment	Phase III	SWTX (ex private)	804	3.0	23.8	1.5
Galápagos	Drugs for the treatment of autoimmune and inflammation disorders	Phase III	GLPG	11'222	0.2	23.6	1.5
2 Alnylam	RNAi therapies for genetic and cardio-metabolic diseases	Market	ALNY	9'574	0.2	22.0	1.4

Development of Share Prices (1/2)



HBM Research, data as of 31 October 2019

Development of Share Prices (2/2)



HBM Research, data as of 31 October 2019

HBM Healthcare Investments Largest Private Investments over the last 5 Years 43 Arcutis IPO or VIELABIC trade sale 찾 SpringWorks PRINCIPIA APTINYX HB ımg Cardialen HARMONY **DBSF** OMOLOG TRUE NORTH 健客 jianke.com bstetrics & bevo Vascular -mAbs ICONIC THERAPEUTICS sphingotec NEURELIS **Dynamics** RM SWIXX & BioPharma Turning Point **farma**listo AnaptysBio BIOSCIENCES 2014 2015 2016 2018 / 2019 2017

Year of initial investment, only investments > CHF 5 million

Data as of 31 October 2019

Strategic Fund Investments



BioVeda China

Invested: 2005 Investment: 8.5 m Investment multiple: 3.6x Ownership: 34%

Healthcare

Fund strategy: Later and growth stage opportunities

Investment thesis: One of the first local investors specialised in the Chinese healthcare market



China	US US
BUILD	FIND
Life Science Companies	Innovative
from Scratch	Life Science Companies
▲ 城 Wu	uXi
水 子	valthcare
秋 本 Ve	ntures

WuXi Healthcare

20 m 2.1x 7%

Healthcare

Access to early stage investment opportunities with a focus on China

Seasoned investment team, former WuXiAppTec, with vast network facilitating / offering deal flow possibilities

Currently no coinvestment



6- Dimensions Capital

> 2018 25 m 1.2x 5%

Healthcare

Invest and build quality platform companies currently missing in China

VC with capabilities in China and U.S. to access innovation and build category leaders in healthcare sectors





Tata Capital

2015 10 m 1.4x 67%

Healthcare

Growth and expansion phase

Partnering with one of the leading on-shore private equity investors in Indian life sciences





Medfocus FAMILY Medfocus

> 2005 16 m 2.5x 100%

Medical devices

Incubator and accelerator concept, selective later stage investments

Access to promising early stage investments in later rounds; "raised" by successful entrepreneurs





HBM Genomics

> 2015 15 m 0.9x 100*%*

Genomics

Early and development stage opportunities

Access to early stage investments in later rounds; Network of top Silicon Valley investors and companies with a focus on genomics

BaseHealth

Data as of 31 October 2019, in CHF

Private Companies with significant Value-Increasing Potential

45

207 Long-chain dicarboxylic acids / bio-based diamine 5 Strong revenue growth and profitable Potentially first company with a commercial scale production of bio-based diamine 5



Narcolepsy (with and without cataplexy)

CATHAY

- Wakix (Pitolisant) now market approved in the US and in the EU for narcolepsy (with or without cataplexy); unlike other wake-promoting agents, Wakix is not scheduled as a DEA controlled substance
- First-in-class, selective, histamine H3 inverse agonist which promotes wakefulness, and reduces the frequency of cataplectic episodes, limited abuse potential

38

NEURELIS

- Diazepam (Valtoco) nasal spray for use in breakthrough epilepsy seizures
- NDA filed, orphan designation in the US and EU
- Major unmet need in epilepsy patients, where no drug is approved for controlling break through seizures

22

20

15



- Full representation service in CEE markets
- Profitable company with net sales exceeding EUR 70 million in 2018; high double-digit sales arowth for 2019
- Signed agreements with 17 multinationals across 17 countries



- India's leading online pharmacy, medicines app and health platform
- Strong sales growth
- Highest ranked medical app on the Indian Google play-store



- Topical formulation of PDE4 inhibitor, Roflumilast studied in mid-stage clinical trials for the treatment of plaque psoriasis and atopic dermatitis
- Roflumilast potentially used as an alternative to steroids
- Various JAK inhibitors in clinical development for dermatological indications

Size corresponds to HBM's book value (in Mio. CHF)

64

Data as of 31 October 2019

46

Promising Public Company Holdings

90

)-mAbs

- Pediatric oncology (neuroblastoma), radioimmunotherapy
- Filing for both lead compounds with the FDA expected in 2019

38

36

27

VIELABIO

- Lead asset is an anti-CD19 antibody (Inebilizumab monotherapy) – potentially first-in-class – in an orphan CNS autoimmune indication known as Neuromyelitis optica spectrum disorder (NMOSD)
- Limited competition, patients often receive off-label immunosuppressants or steroids



- Severe autoimmune diseases (MG, ITP, PV)
- Novel antibody-based therapies, combining the diversity of the llama immune system with antibody engineering

ZogeniX

- Rare neurological disorders (Dravet Syndrome and Lennox Gastaut Syndrome)
- US approval decision for ZX008 in 2020 (based on re-submission in Sept 2019)

- RNAi targeting therapies
- Patisiran which targets TTR amyloidosis was the first approved product in 2018
- Pivotal data for givosiran (porphyria), lumasiran and fitusiran expected over the course of 2019

EsperionTherapeutics

- Cholesterol-lowering drugs, alternative to statins
- Bempedoic Acid (BA) is an orally available drug that lowers LDL ("bad" cholesterol)
- First FDA approval expected in H2 2019



17

22

21

IMMUNOMEDICS; INC.


- Antibody drug conjugate, solid tumors
- Impressive data in 3rd-line, triple negative breast cancer, which led to breakthrough designation from FDA

PRINCIPIA

- Autoimmune / inflammatory diseases and oncology
- PRN1008, a reversible covalent BTK inhibitor
- Highly differentiated and potentially best-in-class small molecule drug platform
- Phase II top-line results in ITP expected in Q4 2019

47

2019 Busy Event Calendar of Main Positions



HBM Research

HBM Healthcare Investments Ltd – Attractions for Investors

48

Growing Industry

Equity investment into promising private and public companies

Expertise

Expertise of the HBM Partners team in selecting investments with attractive risk and reward

Value Creation

Portfolio with significant valueincreasing potential

Commitment

Transparent valuation and reporting, annual cash distribution and share buy-back program

Reasons to Invest in HBM

- Access to a well-diversified portfolio of private and listed companies with daily liquidity
- Portfolio with attractive value-increasing potential, companies with significant growth or IPO plans, plus potential M&A candidates
- Closed-end structure allows optimum exploitation of the value-increasing potential of healthcare companies
- Competitive edge over other investment companies and investment funds with exclusively listed investments
- Stable team: Majority of investment professionals have been with HBM for more than 12 years
- ► HBM is a preferred investment partner, even for larger transactions
- Overall, lower correlation to a "pure" stock market investment thanks to the substantial allocation in the private market
- Quarterly reporting with high level of transparency and direct access to the HBM portfolio management team

About HBM Healthcare Investments Ltd Investment Strategy Healthcare Sector Portfolio Structure Investment Positions Outlook & Concluding Remarks Appendix: Organisation, Team

Timely & Transparent Investment Valuations

- Positions in listed companies are valued at market prices
- Positions in private companies are valued at acquisition cost in the investment currency, except when:
- Portfolio company is valued higher or lower in connection with a new round of financing with a third party lead investor (not strategic investors)
- Portfolio company is performing below expectations, leading to a write down in steps of 25, 50, 75 or 100%
- Portfolio company has significant revenues and profits, in which case an appropriate price/sales or price/earnings multiple is applied ("sales and earnings multiple method")

Negative events are reflected in the valuations as they occur. Positive developments (i.e. good clinical data, partnering deals, etc.) will only be reflected in the valuations if there is a "liquidity event" (financing round with third party investor, IPO or trade sale).

Investor Information

Share Information

Swiss security number	1.262.725
German security number	984345
ISIN	CH 0012627250
CUSIP	H 3553X112
Telekurs	126,126272
SIX Swiss Exchange Ticker	HBMN

Largest shareholders

%	Shareholder	Notification
15-20	Nogra SA, Luxemburg	9.11.2016

Distribution policy

Withholding tax-exempt distribution yield of 3-5% p.a. from par value repayment

Fees

Annual Management fees (paid quarterly)	0.75% of company assets plus 0.75% of the company's market capitalisation
Performance fee (paid annually)	15% on increase in value above the high water mark
High water mark (per share for all outstanding shares)	NAV of CHF 186.86

52

Latort

Board of Directors



Hans Peter Hasler Chairman and Member of the Compensation Committee

Chairman of the Board of Directors MIAC AG since 2012. Member of the Board of Directors Minerva Neurosciences since 2017, member of the Board of Directors Shield Therapeutics plc since 2018

Since 2017 CEO of Vicarius Pharma. Prior to this, international management positions at Wyeth Pharmaceuticals, Biogen and Biogen Idec, as well as Elan Corporation



Prof Dr Dr h.c. mult. Heinz Riesenhuber Vice Chairman and Member of the Audit Committee

Chairman of the Advisory Board Rock Tech Lithium Inc. since 2018; Member of the Investors' Committee Heidelberg Innovation BioScience Venture II GmbH since 2001

Member of the German Parliament 1976 to 2017; German Federal Minister of Research 1982 to 1993; Chairman of German Parliamentary Society 2006 to 2018; numerous directorships



Mario G. Giuliani Member of the Compensation Committee

Member of the Board of Directors Jukka LLC since 2015, NGR (MONACO) SAM since 2015, Giuliani Group SpA since 2010, and Giuliani SpA since 1999; Member of the Investment Committee Royalty Pharma since 2001, and Mosaix Ventures LLP since 2000 as well as various other directorships within the Nogra Group

Previously executive positions and directorships at Giuliani SpA, Recordati SpA, and Nogra Group SA



Dr Eduard Holdener

Board Member

Chairman of the Board of Directors NovImmune S.A. since 2008, CEO since 2016

Medical doctor. Prior to this, specialist in internal medicine and oncology; various international executive positions at F. Hoffmann-La Roche Ltd



Robert A. Ingram

Member of the Compensation and Nominating Committee

Chairman of the Board of Directors Viamet Pharmaceuticals Inc. since 2015, BioCryst Pharmaceuticals Inc. since 2015, Novan Inc. since 2011, and Cree Inc. since 2008

General Partner of Hatteras Venture Partners USA



Dr Rudolf Lanz

Member of the Audit and Nominating Committee

Chairman of the Board of Directors Dr. Rudolf Lanz AG since 2009; Member of the Board of Directors MIAC AG since 2015, and Pearls Fashion Holding AG since 2009

Previously Partner of The Corporate Finance Group and head of M&A & Corporate Finance of Ernst & Young Switzerland

Management HBM Healthcare Investments Zug / Cayman



Dr Andreas Wicki (2001) Chief Executive Officer

Doctorate in chemistry and biochemistry; since 2001 Chief Executive Officer HBM Healthcare Investments Ltd and HBM Partners Ltd. Prior to this, chief executive of several pharmaceutical companies (1988 to 2001), investment and venture capital advisor (1993 to 2001)

Member of the Board of Directors Harmony Biosciences since 2017, Vitaeris Inc. since 2016, Pacira Pharmaceuticals Inc. since 2007, HBM Healthcare Investments (Cayman) Ltd since 2001, and Buchler GmbH since 2000



Erwin Troxler (2005) Chief Financial Officer

Economist and Swiss Certified Public Accountant; since 2005 HBM Healthcare Investments Ltd and HBM Partners Ltd, since 2011 Chief Financial Officer. Prior to this, auditor PricewaterhouseCoopers Ltd (1996 to 2002) and Julius Baer Family Office (2002 to 2005)

Chairman of the Swiss Association of Investment Companies (SAIC) since 2014



Jean Marc Lesieur (2001) Managing Director and Member of the Board of Directors HBM Healthcare Investments (Cayman) Ltd

More than twenty years of experience in trust and corporate management and administration. Before joining HBM Healthcare Investments, he was with Vontobel Private Equity Management Ltd, acting as an executive director with responsibilities for personnel and all corporate and company management matters of the private equity business in the Cayman Islands

Associate of the Chartered Institute of Bankers, ACIB (Trustee), a member of the Society of Trust and Estate Practitioners (STEP) and a Notary Public in the Cayman Islands. He was educated in the Cayman Islands and England

Private Equity Team



Dr Matthias Fehr, CFA (2002)

Head Private Equity

Over twenty years of experience in private and public equity investment management and research

MSc and PhD in chemistry from ETH, Zurich Former senior sell-side analyst at Lombard Odier for biotech and medical technology industries; former scientist at the Swiss Federal Institute of Technology



Dr Priyanka Belawat (2007)

Investment Advisor

Over ten years of experience in venture and private equity investing in the healthcare space in the US, Europe and selected emerging markets

Holds a doctorate in molecular biology and genetics from the University of Zurich and a post-doc at HKUST



Dr Alexander Asam, MBA (2007) Investment Advisor

vestment Advisor

More than twenty years of experience in the life sciences and private equity businesses MBA degree from ASTON Business School, Birmingham and a MSc and PhD in chemistry from University of Heidelberg

Former managing director and partner of Deutsche Venture Capital / Deutsche Bank. Various positions at Hoechst, Aventis and LION Bioscience



Dr Emil Bujak (2015)

Investment Advisor

Over six years of experience in life sciences, including one year in investment analysis and industry report preparation

Holds a PhD in Pharmaceutical Sciences and an MSc in Medicinal and Industrial Pharmaceutical Sciences from ETH Zurich

Prior experience as registered pharmacist



Dr Ulrich Geilinger (2001)

Senior Investment Advisor

More than 25 years of experience in the Venture Capital Industry PhD ETH Zurich in Natural Sciences and

Industrial Engineering

Previously in management functions at Innoventure, Credit Suisse, Apax and Vontobel.



Dr Michael Buschle (2017)

Investment Advisor

More than 25 years of experience in biotech and pharma

PhD from the University of London. Research at St. Jude's Children's Research Hospital, Boehringer Ingelheim-owned Institute of Molecular Pathology, Vienna

Co-founder of Intercell with successful IPO, CSO of Glenmark Pharma



Dr Chandra P. Leo, MBA (2007)

Investment Advisor

Over fifteen years of experience in private equity, clinical practice and biomedical research

Completed medical studies in Berlin and London, doctoral degree from Freie Universität Berlin, MBA degree from INSEAD

Former postdoctoral scientist at Stanford University, physician at University Hospital Leipzig and principal at Wellington Partners

	-	
	-	
	_	
	-	
	-	
	-	
-		

Dr Thomas Thaler (2006)

Investment Advisor

Over 25 years of experience in the investment management, financial research and in the biotechnology and medical technology industry

PhD in life sciences and MSc in biochemistry and a master's degree in business administration from ETH Zurich

Previously senior equity analyst at Bank Julius Baer and in senior management positions with Sulzer Medica, Schneider and Boston Scientific



Public Equity Team



Dr Ivo Staijen, CFA (2003)

Head Public Equity

Over 20 years experience in the pharma industry and in investment analysis and portfolio management

PhD in biotechnology from ETH Zurich and MSc in chemistry from the University of Groningen

Previously senior biotechnology analyst at Bank Sarasin and department head at MDS Pharma Services



Steve Chen, CFA (2019)Investment Advisor (Hong Kong)

Over 15 years of investing experience with focus on China and global healthcare

MBA from Wharton Business School, MSc in Biochemistry and Molecular Biology from Georgetown and BSc from Nankai University

Previously managed trading portfolio for Barclays (NY) and Huatais' HK subsidiary and was PM for a large closed-end listed fund in China



Gavin MacGregor (2017)**Investment Advisor**

Over 13 years' experience in the pharma industry and in global healthcare investment analysis

1st Class BSc in Biomedical Sciences from the University of Manchester and a Chartered Management Accountant (CIMA)

Previously senior global healthcare analyst at Martin Currie Investment Management. European pharmaceuticals analyst at Credit Suisse and Lehman Brothers



Miles Schofield (2007)

Trading & Execution

Over 15 years experience in trading & execution

Bachelors of Science (Hons) degree from the Open University UK

Previously in US Equities Middle Office activities at Salomon Smith Barney and Citigroup



Mirjam Heeb (2019)**Investment Advisor**

Over 15 years experience in the pharma industry and global healthcare investment analysis and portfolio management

MSc in Molecular Biology from the University of Basel and McGill University, Montreal

Previously senior portfolio manager of GAM Health Innovation Fund, senior manager with Vifor Pharma, sell-side and buy-side analyst. portfolio manager at Bellevue Group.



Ny Ken (2004)

Investment Control

More than 10 years experience in trading & execution and administration

Bachelor in business administration from Zurich University of Applied Sciences

Previously in administrative functions at HBM Partners AG



Michael Jasulavic (2012)

Investment Advisor to HBM Partners

Over ten years of experience in healthcare investment research, strategy and trade execution

MS in Medical Science from MCP/Hahnemann Universitv

Previously biotechnology analyst at Traxis Partners. Sivik Global Healthcare and Jefferies Asset Management



Thomas Heimann (2010)

Risk Manager and Analyst

Over eight years of experience in Investment Research, Analysis, FINMA Risk Management and client services

MSc and BSc in Banking & Finance from the Lucerne University of Applied Sciences

Previously in investment analysis and valuation and in client advisory at a Swiss bank

Disclaimer

This document is intended to be for information purposes only. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument and should therefore not be relied on for accounting, legal or tax advice, or investment recommendations.

Information herein is believed to be reliable but HBM does not warrant its completeness or accuracy. No responsibility can be accepted for errors of fact or opinion. Reliance should not be placed on the views and information in the document when taking individual investment and/or strategic decisions. HBM has expressed its own views in this document and these may change.

Past performance is not a reliable indicator of future results, prices of shares and the income from them may fall as well as rise and investors may not get back the amount originally invested. All investments involve risk including the risk of possible loss of the invested amount. Investors should consider all potential risks and further disclosure information associated with the investment disclosed in the fund documents and the appropriateness with their financial profile and objectives. Changes in foreign-exchange rates may also cause the value of investments to fall as well as rise.

Some information quoted was obtained from external sources HBM considers to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions. Third party data is owned or licensed by the data provider and may not be reproduced or extracted and used for any other purpose without the data provider's consent. Third party data is provided without any warranties of any kind. The data provider and HBM shall have no liability in connection with third party data.

Issued by HBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland.

Your Contact

HBM Healthcare Investments Ltd

Bundesplatz 1

6301 Zug

Switzerland

Phone+41 41 710 75 77Fax+41 41 710 75 78

investor.relations@hbmhealthcare.com www.hbmhealthcare.com